Novartis v. Novugen: MEK Inhibitor Patent Suit Dismissed Without Prejudice
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novartis AG, et al. v. Novugen Oncology SDN. BHD., et al. |
| Case Number | 1:23-cv-01449 (Fed. Cir. D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2023 – Mar 2024 75 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Trametinib Dimethyl Sulfoxide Tablets (0.5 mg and 2 mg) |
Case Overview
In a swift procedural conclusion to a high-stakes pharmaceutical patent dispute, plaintiffs Novartis AG, Novartis Pharma AG, and Japan Tobacco, Inc. voluntarily dismissed their infringement action against Novugen Oncology SDN. BHD., Novugen Pharma (USA), LLC, and Makro Technologies, Inc. — without prejudice — just 75 days after filing. Case No. 1:23-cv-01449, adjudicated in the U.S. District Court for the District of Delaware before Chief Judge Gregory B. Williams, centered on five patents protecting trametinib dimethyl sulfoxide tablets (0.5 mg and 2 mg), a critical MEK inhibitor used in oncology treatment.
The dismissal without prejudice leaves the door open for future litigation, signaling that the resolution — whether through settlement, licensing negotiation, or strategic repositioning — may not be the final chapter. For patent attorneys tracking pharmaceutical patent infringement trends, IP professionals managing oncology drug portfolios, and R&D teams navigating generic drug development risk, this case offers instructive lessons in ANDA-related patent strategy and litigation management.
The Parties
⚖️ Plaintiffs
Global pharmaceutical leaders with substantial oncology intellectual property portfolios, including patents covering the branded MEK inhibitor Mekinist® (trametinib).
Co-plaintiff holding joint patent rights relevant to trametinib’s chemical composition and formulation, reflecting a common licensing and co-ownership structure in innovative drug development.
🛡️ Defendants
Malaysian pharmaceutical manufacturer and its U.S. affiliate, along with Makro Technologies, Inc., accused of infringing patents through generic trametinib development.
The Patents at Issue
This high-stakes pharmaceutical patent dispute centered on five U.S. patents protecting trametinib dimethyl sulfoxide tablets (0.5 mg and 2 mg), a critical MEK inhibitor used in oncology treatment. These patents collectively cover the chemical composition, formulation, and therapeutic use of trametinib, a small-molecule MEK1/MEK2 inhibitor.
- • US7378423B2 – Application No. 11/150,792
- • US9155706B2 – Application No. 14/103,193
- • US9399021B2 – Application No. 14/103,092
- • US8580304B2 – Application No. 13/330,949
- • US9271941B2 – Application No. 14/044,139
Developing a generic pharmaceutical?
Ensure your product doesn’t infringe existing patents with a comprehensive FTO analysis.
The Verdict & Legal Analysis
Outcome
On March 4, 2024, plaintiffs voluntarily dismissed the action without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1). No damages were awarded. No injunctive relief was entered. The dismissal was self-executing under Rule 41(a)(1), requiring no court order, which indicates it was filed before the defendant served an answer or motion for summary judgment.
Verdict Cause Analysis
The stated cause of action was patent infringement. Given the product at issue — a generic formulation of a branded oncology drug — and the Hatch-Waxman statutory framework, the infringement claim most likely arose from a paragraph IV ANDA certification asserting that the asserted patents were invalid, unenforceable, or would not be infringed by the generic product.
Because the case resolved before any substantive rulings, there is no public claim construction order, no validity determination, and no infringement finding to analyze. However, the without prejudice nature of the dismissal is legally significant: plaintiffs preserved their right to refile the same claims, suggesting they did not concede the merits.
Legal Significance
Rule 41(a)(1) dismissals in Hatch-Waxman cases frequently signal confidential licensing deals or negotiated exclusivity windows rather than substantive patent weaknesses. The absence of any defendant filing prior to dismissal — which is a prerequisite for a plaintiff-only Rule 41(a)(1) notice — suggests the defendants had not yet formally appeared or responded, placing this resolution in the very earliest stage of litigation.
For the five asserted patents, their validity and enforceability remain untested by this proceeding. No adverse precedent was created. The patents remain in force.
Strategic Takeaways
For Patent Holders: A multi-patent assertion strategy (five patents across related application families) creates settlement leverage early. Plaintiffs here effectively used the full weight of their portfolio to drive a rapid resolution without substantive litigation costs.
For Accused Infringers (Generic Manufacturers): Early resolution — before answer or motion practice — avoids costly litigation while potentially securing negotiated market entry dates. The without-prejudice dismissal, however, means generic developers must evaluate ongoing patent risk before commercial launch.
For R&D and Regulatory Teams: ANDA filers targeting branded oncology drugs with complex multi-patent portfolios should conduct thorough Freedom to Operate (FTO) analyses across all related patent families. A single unchallenged patent can support a new infringement action post-dismissal.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all 5 related patents in the trametinib space
- See which companies are most active in MEK inhibitor patents
- Understand patent claim scope and formulation protection
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic trametinib product.
- Input your product formulation or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
Ongoing Risk
Dismissal without prejudice means risk persists
5 Key Patents
On trametinib composition & formulation
Hatch-Waxman Insights
Understand ANDA strategy
✅ Key Takeaways
Rule 41(a)(1) dismissals before defendant answer suggest early settlement or licensing resolution — monitor for refilings.
Search related case law →Multi-patent assertion across related families maximizes Hatch-Waxman stay benefits and settlement leverage.
Explore Hatch-Waxman trends →Delaware remains the premier venue for pharmaceutical patent infringement under the Hatch-Waxman framework.
View D. Del. litigation data →Frequently Asked Questions
Five U.S. patents were asserted: US7378423B2, US9155706B2, US9399021B2, US8580304B2, and US9271941B2, covering trametinib dimethyl sulfoxide composition and formulation.
Plaintiffs filed a voluntary dismissal under FRCP Rule 41(a)(1) before defendants served an answer, most likely reflecting an out-of-court resolution. The without-prejudice designation preserves plaintiffs’ right to refile.
The case reinforces that multi-patent Hatch-Waxman enforcement strategies can achieve rapid resolutions. Generic developers targeting trametinib must address all asserted patent families to mitigate ongoing litigation risk.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-01449
- USPTO Patent Center — Asserted Patents
- CourtListener — Delaware Pharmaceutical Patent Litigation
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.